We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Eloxx

News List

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis firstwordpharma
July 07, 2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.
Eloxx Pharmaceuticals Acquires Zikani Therapeutics contractpharma
April 02, 2021
Eloxx Pharmaceuticals, Inc. has acquired Zikani Therapeutics, Inc. in an all-stock transaction, combines complementary ribosomal RNA-targeted genetic therapy platforms and therapies for the treatment of rare diseases and oncology.
Eloxx Pharmaceuticals: Promising Treatment for Rare Genetic Diseases biospace
April 13, 2018
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.